Life Extension Magazine®

Man effected by a atherosclerotic-induced disorder grasping his chest

The LDL Cholesterol Debate

A recent review paper argues that LDL levels should be lower than commonly advocated. Life Extension® evaluated this and other data to assess better ways to reduce cardiovascular risks.

By William Faloon.

William Faloon
William Faloon

One of the great controversies in recent decades is what level of LDL cholesterol is associated with the lowest risk of occlusive arterial disease (atherosclerosis).1

Those with a genetic propensity to over-produce cholesterol suffer premature atherosclerosis and increased cardiovascular disease incidence.2,3

This undisputed fact has been used to help support the importance of lowering very high LDL cholesterol.

The debate centers around what constitutes "optimal" LDL blood levels for normal and high-risk individuals.

With age, LDL often elevates to ranges that cause or contribute to arterial blockages.4,5

This is concerning because atherosclerosis remains the leading cause of disease, disability, and death in the United States.6

I am aware of different positions that well informed people take on the "LDL Cholesterol Debate".

The data presented in this editorial reflect views of those who argue for lower LDL blood levels to reduce atherosclerotic-induced disorders.

Options for achieving safer LDL blood levels are provided.

Differences in opinion about "optimal" LDL cholesterol values have caused fierce debate for many decades.

While clear consensus remains elusive, a recent review paper argues that based upon all current evidence, the LDL level to prevent atherosclerosis should be lower than commonly advocated.7

The authors of the review suggest targeting LDL to as low as 40 mg/dL for patients at highest risk. This is similar to the LDL level of newborn infants.

These authors acknowledge that these low LDL levels will be challenging to achieve and may not be feasible for all patients without use of LDL-reducing drugs.

For patients with no significant additional risk factors for cardiovascular disease, the authors suggest that keeping LDL below 85 mg/dL from birth throughout life would likely delay onset of atherosclerosis complications until age 100 years or more.7

This conflicts with what some in the alternative and conventional medical communities recommend. Yet there are data to argue that LDL is a "vascular toxin."7

The authors point to mathematical modeling of observational data that suggests atherosclerosis risk is lowest at an LDL level of around 38 mg/dL.

Current LDL cholesterol guidelines vary between European and American experts, as well as among different expert working groups within different countries.

The current consensus generally suggests LDL blood levels should be below 100 mg/dL in healthy individuals and below 70 mg/dL in people at high coronary risk.

I'll describe how these new "lower" LDL recommendations apply later in this article.

Modern-day Achilles Tendon

Cardiovascular diseases are the greatest threats to our healthy longevity.

We at LifeExtension® have long advocated that more needs to be done to prevent and treat atherosclerosis.

Arterial/vascular disease not only causes heart attacks and ischemic strokes, but also contributes to:

  • Several types of Dementia8-10
  • Peripheral arterial disease11-13
  • Heart failure13-15
  • Renal artery stenosis11,16,17
  • Carotid artery stenosis and embolization18
  • Kidney failure19
  • Hypertension20
  • Aortic calcification/stenosis21
  • Mesenteric artery disease22
  • Erectile dysfunction23-25
  • Frailty26,27
  • Accelerated aging28

Arterial disease represents our greatest vulnerability. It's an Achilles tendon to our continued existence.

Treating Atherosclerosis More Aggressively!

A review article published December 2022 in the American Journal of Preventive Cardiology made provocative arguments for achieving very low LDL blood levels.

For those who don't want to read this full-text document, I summarize the following salient points:7

  • Atherosclerosis is a preventable disease.
  • Elevated LDL is a necessary factor for atherogenesis induction.
  • Observational data from retrospective analyses, prospective longitudinal data, and interventional randomized clinical trials support LDL as a significant risk factor for atherosclerosis.
  • The percentage of high- and very high-risk patients who achieve optimized LDL target reductions is low and has remained low for the last 30 years.
  • The majority of patients at atherosclerotic risk are inadequately treated, leaving them vulnerable to disease progression, acute cardiovascular events, and poor aging.
  • The relationship between LDL cholesterol and risk for atherosclerotic cardiovascular disease is one of the most highly established/investigated issues in the entirety of modern medicine.

The above bullet points may enlighten some of you, while causing disagreement amongst others.

I next describe the most controversial aspect of this December 2022 published review.7

Optimal LDL Blood Levels: “20-40 mg/dL”?

The authors of this 2022 review argue that the optimal LDL appears to be the level present at birth (20–40 mg/dL). They also recognize that that this range is probably not necessary for everyone nor practical to attain widely.

These authors suggest that LDL below 40 mg/dL seems the most effective goal for patients in the category of more advanced atherosclerosis, i.e., vascular disease patients at highest risk.

Recall that the current target advocated by many lipid authorities, but not all, for those at high cardiovascular risk is LDL below 70 mg/dL.

What you've read so far represents quite a difference of opinion! Especially when today's general recommended LDL reference range is somewhere below 100 mg/dL.  

To put this in historic perspective, in the 1980s the upper limit for LDL readings was around 160 mg/dL,29 which is considered high by today's standards.

We at Life Extension® argued back then that LDL blood levels should be below 100 mg/dL. Subsequent research helped validate this, yet there is now published data to suggest even lower LDL targets.

Data Supporting Lower LDL Levels

The authors of the December 2022 review cite the following data to argue that today's LDL reference ranges are too high:

  • Animals and humans who maintain low cholesterol levels early in life have very little atherosclerosis.
  • Very low LDL levels are observed among hunter-gatherer populations who have less evidence of atherosclerotic disease.
  • The LDL level where there is no excess risk of atherosclerotic cardiovascular disease is approximately 38 mg/dL. (This is strikingly low by most current standards.) 
  • Over a 26.5- year follow-up, even baseline LDL under 100 mg/dL resulted in a continuous rise in risk for coronary heart disease mortality. (This suggests the importance of targeting LDL lower than current standards.)30,31
  • Average LDL level of men presenting with an acute coronary syndrome is approximately 150 mg/dL.32 (This LDL level was viewed as "normal" in the 1980s when heart attack rates were higher.)
  • These lower LDL levels are difficult to achieve in a modern society and may not be necessary for people not at high cardiovascular disease risk.
  • Unfortunately, aging itself is the greatest coronary artery disease risk factor.33
  • In addition, most of us have had exposure to secondhand tobacco smoke and less than ideal dietary practices in our early years. This inflicts arterial damage that can manifest as cardiovascular disease in later life.
  • One way to reduce cardiovascular risk is to target LDL to lower ranges depending on individual circumstances.

LDL-Lowering Strategies

Decreasing intake of saturated fat (meat, butter, cheese, and full-fat dairy) to less than 7% of daily calorie intake can reduce LDL by 8% to 10%.34

The problem is that a typical aging person's LDL is far above 120 mg/dL.

Even if they stick with a rigid diet, a 10% decrease translates into an LDL level of 108 mg/dL, which may be twice as high as ideal for many individuals.

Statin drugs have been attacked by alternative medicine for decades. Yet the side-effect risks of modest statin drug dosing may be trivial compared to the deadly impact of elevated LDL and related lipids like apolipoprotein B (ApoB).35,36

Dangerously high levels of ApoB occur commonly in people with high LDL.37 The statin drug rosuvastatin was shown to reduce ApoB levels by 36%-45%, which was better than other statin drugs tested.38

Life Extension® Magazine published an article in 2003 showing that every other day dosing of a modest statin (10 mg/atorvastatin) yielded significant benefits with zero side effects. And for some of you, a modest statin dose taken every other day might push your LDL down to an ideal range.39

Those with higher LDL levels may take a modest dose statin combined with another drug (ezetimibe) that blocks intestinal reabsorption of cholesterol.40 Others need a higher dose statin drug to achieve LDL below 40 -70/mg/dL depending on their cardiovascular risk factors.

An expensive class of drugs (PCSK-9 inhibitors) such as Repatha® can slash LDL to below 30 mg/dL. Insurance companies often refuse to pay the high price of this drug.41,42

I am aware of the concerns raised about statin drug side effects. Overlooked by many, however, is the ability of statin drugs to lower elevated LDL and ApoB.

There has been a multi-decade debate about what optimal LDL blood levels should be. As it relates to the dangers of elevated ApoB, there is virtual unanimity, i.e., keep your ApoB levels in low ranges to reduce atherosclerotic risks.

A Non-Drug Approach!

An article on page 36 of this month's issue describes a botanical extract that has demonstrated LDL-lowering effects.

The latest human study showed a 21.8% decline in LDL. The placebo arm of this study had a 3.83% LDL increase.43

In addition to reduced LDL, this plant extract was shown to lower total cholesterol, triglycerides, and C-reactive protein* while boosting beneficial HDL.

These favorable blood changes were accompanied by improved endothelial function, a measure of arterial health.

For many readers of Life Extension® Magazine, a 21% reduction in LDL will achieve desired levels. Others might need a statin drug in addition to this plant extract to achieve optimal LDL ranges.

*C-reactive protein is a marker of chronic inflammation. Elevated C-reactive protein has been shown in some studies to be a greater cardiovascular risk factor than high LDL cholesterol.44

Interesting Maps

The maps copied on this page show an association of high cholesterol prevalence and increased incidence of stroke and lower life expectancy.

While these maps show correlation and not causation, they depict shorter lifespans in areas where most people fail to take care of their health.

Map A shows that concentrations of counties with the highest cholesterol prevalence—meaning the top quintile—are located primarily in Mississippi, Louisiana, Arkansas, Oklahoma, Texas, Kentucky, Tennessee, Michigan, Maine, South Carolina, and Kansas.46

A.High Cholesterol Prevalence, 2018-2020 Adults Screened, 18+, by County

Source: CDC.


B. Life Expectancy at Birth for U.S. States and Census Tracts, 2010-201547

Source: CDC.


C. Stroke Death Rates, 2018-2020 Adults, Ages 35+, by County48

Source: CDC.


D. Life Expectancy in the U.S. in 202049
Nine-Year Disparity in Human Longevity
(Note lighter colors below reflect reduced life expectancy.)

Source: CDC.

Your Blood Test Results are what Matter!

The objective of a lipid-lowering program is to achieve blood levels that have been shown to reduce cardiovascular risks.

Low-cost blood tests provide readings of artery-clogging lipids including LDL, ApoB, and triglycerides.

Current guidelines generally suggest LDL readings over 99 mg/dL are potentially dangerous.

In recent years, those with cardiovascular risks have been advised to drop their LDL to below 70 mg/dL.

A 2022 published review provides evidence that those patients at highest cardiovascular risk may benefit from targeting LDL below 40 mg/dL.7

If a blood test reveals higher than optimal LDL or other vascular risk factors, initiate the appropriate corrective action(s). Then retest in a few months to check how the approach works for you.

Assess Your Cardiovascular Risks

The time to lower atherogenic risks is before one suffers a heart attack or ischemic stroke.

I continue to be surprised when asking educated people what their LDL, triglyceride, and C-reactive protein (CRP) levels are. Most respond by saying they have no idea.

I am aware of the different positions that informed people take on the "LDL Cholesterol Debate".

The data presented in this editorial reflect the views of those who argue for lower LDL blood levels to reduce cardiovascular risks.

The blood test panel on the next page costs hundreds of dollars at commercial labs but is available to Life Extension® readers at a steeply discounted price.

The Cardio Core Essentials Panel costs only $68 (item # LC100086) if you order by December 31, 2023.

You can obtain this blood test panel by calling (24-Hours) 1-800-208-3444 or visit:

For longer life,

For Longer Life

William Faloon


  1. Yamaguchi T, Morino K. Perivascular mechanical environment: A narrative review of the role of externally applied mechanical force in the pathogenesis of atherosclerosis. Front Cardiovasc Med. 2022;9:944356.
  2. Available at: Accessed July 5, 2023.
  3. Available at: Accessed July 5, 2023.
  4. Hill MF, Bordoni B. Hyperlipidemia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
  5. Available at: Accessed July 5 2023.
  6. Available at: Accessed July 6, 2023.
  7. Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022 Dec;12:100371.
  8. Gottesman RF, Albert MS, Alonso A, et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017 Oct 1;74(10):1246-54.
  9. Cederwald BFv, Josefsson M, Wåhlin A, et al. Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia. Neurology. 2022;98(20):e2013-e22.
  10. Available at: Accessed May, 8, 2023.
  11. Imori Y, Akasaka T, Ochiai T, et al. Co-existence of carotid artery disease, renal artery stenosis, and lower extremity peripheral arterial disease in patients with coronary artery disease. Am J Cardiol. 2014 Jan 1;113(1):30-5.
  12. Available at: Accessed May, 3, 2023.
  13. Samsky MD, Hellkamp A, Hiatt WR, et al. Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. J Am Heart Assoc. 2021 Jun 15;10(12):e018684.
  14. Duprez DA. Arterial stiffness/elasticity in the contribution to progression of heart failure. Heart Fail Clin. 2012 Jan;8(1):135-41.
  15. Available at: Accessed May, 5, 2023.
  16. Lao D, Parasher PS, Cho KC, et al. Atherosclerotic renal artery stenosis--diagnosis and treatment. Mayo Clin Proc. 2011 Jul;86(7):649-57.
  17. Bokhari MR, Bokhari SRA. Renal Artery Stenosis. StatPearls . Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
  18. Available at: Accessed May, 5 2023.
  19. Available at: Accessed May, 5, 2023.
  20. Weber T, Lang I, Zweiker R, et al. Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension. Wien Klin Wochenschr. 2016 Jul;128(13-14):467-79.
  21. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008 Jun 3;117(22):2938-48.
  22. Krishnamurthy G, Menon A, Kannan K, et al. Coronary artery disease and mesenteric artery stenosis - Two sides of the same coin? - Long term prospective analysis. Intractable Rare Dis Res. 2019 Nov;8(4):245-51.
  23. Kumagai H, Yoshikawa T, Myoenzono K, et al. Sexual Function Is an Indicator of Central Arterial Stiffness and Arterial Stiffness Gradient in Japanese Adult Men. J Am Heart Assoc. 2018 May 5;7(10).
  24. Assar ME, Angulo J, Garcia-Rojo E, et al. Early manifestation of aging-related vascular dysfunction in human penile vasculature-A potential explanation for the role of erectile dysfunction as a harbinger of systemic vascular disease. Geroscience. 2022 Feb;44(1):485-501.
  25. Meller SM, Stilp E, Walker CN, et al. The link between vasculogenic erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic factors and endovascular therapy. J Invasive Cardiol. 2013 Jun;25(6):313-9.
  26. Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. Eur Heart J. 2014 Jul;35(26):1726-31.
  27. Liperoti R, Vetrano DL, Palmer K, et al. Association between frailty and ischemic heart disease: a systematic review and meta-analysis. BMC Geriatr. 2021 Jun 10;21(1):357.
  28. Hata Y, Mochizuki J, Okamoto S, et al. Aortic calcification is associated with coronary artery calcification and is a potential surrogate marker for ischemic heart disease risk: A cross-sectional study. Medicine (Baltimore). 2022 Jul 22;101(29):e29875.
  29. Available at: Accessed July 6, 2023.
  30. Shapiro MD, Bhatt DL. “Cholesterol-Years” for ASCVD Risk Prediction and Treatment∗. Journal of the American College of Cardiology. 2020 2020/09/29/;76(13):1517-20.
  31. Abdullah SM, Defina LF, Leonard D, et al. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation. 2018;138(21):2315-25.
  32. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. The American Journal of Cardiology. 1995 1995/09/28/;76(9, Supplement 1):69C-77C.
  33. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019 Apr 27;6(2).
  34. Available at: Accessed July 5, 2023.
  35. Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016 Nov;32(6):631-9.
  36. Dayar E, Pechanova O. Targeted Strategy in Lipid-Lowering Therapy. Biomedicines. 2022 May 8;10(5).
  37. Tani S, Yagi T, Atsumi W, et al. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017 Oct 2;16(1):123.
  38. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clinical Therapeutics. 2004 2004/09/01/;26(9):1388-99.
  39. Available at: Accessed July 5, 2023.
  40. Available at: Accessed July 6, 2023.
  41. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 Oct 11;146(15):1109-19.
  42. Fala L. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.
  43. Usharani P, Merugu PL, Nutalapati C. Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study. BMC Complement Altern Med. 2019 May 6;19(1):97.
  44. Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023 Apr 15;401(10384):1293-301.
  45. Available at: Accessed July 21, 2023.
  46. Available at: Accessed July 6, 2023.
  47. Available at: Accessed July 6, 2023.
  48. Available at: Accessed July 6, 2023.
  49. Available at: life_expectancy/life_expectancy.htm Life Expectancy at Birth by State. Accessed July 6, 2023.
  50. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39.